Cellectar Biosciences (Warrant)
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CLRBZ and buy or sell other stocks, ETFs, and their options commission-free!About CLRBZ
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CEOJames V. Caruso
CEOJames V. Caruso
Employees—
Employees—
HeadquartersFlorham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded1996
Founded1996
Employees—
Employees—
CLRBZ Key Statistics
Market cap—
Market cap—
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high—
52 Week high—
52 Week low—
52 Week low—
CLRBZ News
TipRanks 21h
Cellectar Biosciences price target lowered to $14 from $18 at Roth CapitalRoth Capital lowered the firm’s price target on Cellectar Biosciences (CLRB) to $14 from $18 and keeps a Buy rating on the shares following the Q4 report. The F...
TipRanks 23h
Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year“2025 was a productive year for Cellectar, marked by disciplined execution across our pipeline and meaningful clinical, regulatory, and operational achievements...